{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:02:03Z","timestamp":1770512523935,"version":"3.49.0"},"reference-count":68,"publisher":"Georg Thieme Verlag KG","issue":"13","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>After the first cases of primary aldosteronism were described and characterized by Conn, a substantial body of experimental and clinical evidence about the long-term effects of excess aldosterone on the cardiovascular system was gathered over the last 5 decades. The prevalence of primary aldosteronism varies considerably between different studies among hypertensive patients, depending on patient selection, the used diagnostic methods, and the severity of hypertension. Prevalence rates vary from 4.6 to 16.6% in those studies in which confirmatory tests to diagnose primary aldosteronism were used. There is also growing evidence indicating that prolonged exposure to elevated aldosterone concentrations is associated with target organ damage in the heart, kidney, and arterial wall, and high cardiovascular risk in patients with primary aldosteronism. Therefore, the aim of treatment should not be confined to BP normalization and hypokalemia correction, but rather should focus on restoring the deleterious effects of excess aldosterone on the cardiovascular system. Current evidence convincingly demonstrates that both surgical and medical treatment strategies beneficially affect cardiovascular outcomes and mortality in the long term. Further studies can be expected to provide better insight into the relationship between cardiovascular risk and complications and the genetic background of primary aldosteronism.<\/jats:p>","DOI":"10.1055\/s-0035-1565124","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:07:10Z","timestamp":1447805230000},"page":"973-980","source":"Crossref","is-referenced-by-count":41,"title":["Cardiovascular Risk in Primary Hyperaldosteronism"],"prefix":"10.1055","volume":"47","author":[{"given":"E.","family":"Warcho\u0142-Celi\u0144ska","sequence":"first","affiliation":[{"name":"Department of Hypertension, Institute of Cardiology, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. M.","family":"Lenders","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universitat Dresden, Dresden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Januszewicz","sequence":"first","affiliation":[{"name":"Department of Hypertension, Institute of Cardiology, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Prejbisz","sequence":"additional","affiliation":[{"name":"Department of Hypertension, Institute of Cardiology, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2015,11,17]]},"reference":[{"key":"ref1","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"J W Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"ref2"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1210\/jc.2008-0104","article-title":"Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline","volume":"93","author":"J W Funder","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function","volume":"29","author":"J M Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"L A Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"E R Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"R Rocha","year":"1998","journal-title":"Hypertension"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"G Mancia","year":"2013","journal-title":"Eur Heart J"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1530\/EJE-14-0537","article-title":"Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension","volume":"172","author":"G Piaditis","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref10","first-page":"447","article-title":"Primary aldosteronism-part I: prevalence, screening, and selection of cases for adrenal vein sampling","volume":"21","author":"G P Rossi","year":"2008","journal-title":"J Nephrol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/HYPERTENSIONAHA.106.086116","article-title":"Is there an unrecognized epidemic of primary aldosteronism?","volume":"50","author":"D A Calhoun","year":"2007","journal-title":"Pro. Hypertension"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/HYPERTENSIONAHA.106.086124","article-title":"Is there an unrecognized epidemic of primary aldosteronism?","volume":"50","author":"N M Kaplan","year":"2007","journal-title":"Con. Hypertension"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s11906-010-0134-2","article-title":"Prevalence and diagnosis of primary aldosteronism","volume":"12","author":"G P Rossi","year":"2010","journal-title":"Curr Hypertens Rep"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1161\/01.HYP.0000079505.25750.11","article-title":"Primary aldosteronism and hypertensive disease","volume":"42","author":"L Mosso","year":"2003","journal-title":"Hypertension"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"G P Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(08)60834-X","article-title":"Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study","volume":"371","author":"S Douma","year":"2008","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/jhh.2013.32","article-title":"Clinical characteristics of patients with resistant hypertension: the RESIST-POL study","volume":"27","author":"E Florczak","year":"2013","journal-title":"J Hum Hypertens"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1055\/s-0033-1343448","article-title":"Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn\u2019s registry","volume":"45","author":"E Fischer","year":"2013","journal-title":"Horm Metab Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-0034-1367033","article-title":"Aldosterone to active Renin ratio as screening test for primary aldosteronism: reproducibility and influence of orthostasis and salt loading","volume":"46","author":"S Pilz","year":"2014","journal-title":"Horm Metab Res"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1055\/s-0035-1548868","article-title":"Renin and aldosterone measurements in the management of arterial hypertension","volume":"47","author":"A Viola","year":"2015","journal-title":"Horm Metab Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.jacc.2010.01.032","article-title":"Aldosterone\/renin ratio determines peripheral and central blood pressure values over a broad range","volume":"55","author":"A Tomaschitz","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa033263","article-title":"Serum aldosterone and the incidence of hypertension in nonhypertensive persons","volume":"351","author":"R S Vasan","year":"2004","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1161\/01.HYP.31.3.843","article-title":"Circadian blood pressure variation in hypertensive patients with primary hyperaldosteronism","volume":"31","author":"G A Mansoor","year":"1998","journal-title":"Hypertension"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.33549\/physiolres.930042","article-title":"Twenty-Four hour blood pressure profile in subjects with different subtypes of primary aldosteronism","volume":"50","author":"T Zelinka","year":"2001","journal-title":"Physiol Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1524-6175.2006.05712.x","article-title":"Ambulatory blood pressure monitoring in secondary arterial hypertension due to adrenal diseases","volume":"8","author":"M Ceruti","year":"2006","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","article-title":"Aldosterone excess and resistance to 24-h blood pressure control","volume":"25","author":"E Pimenta","year":"2007","journal-title":"J Hypertens"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/bjs.9744","article-title":"Systematic review of surgery and outcomes in patients with primary aldosteronism","volume":"102","author":"A Muth","year":"2015","journal-title":"Br J Surg"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/HJH.0b013e328350225d","article-title":"Blood pressure and medication changes following adrenalectomy for unilateral primary aldosteronism: a follow-up study","volume":"30","author":"P van der Linden","year":"2012","journal-title":"J Hypertens"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjhyper.2005.08.011","article-title":"Cardiac consequences of aldosterone excess in human hypertension","volume":"19","author":"G P Rossi","year":"2006","journal-title":"Am J Hypertens"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1055\/s-0031-1291318","article-title":"Aldosterone and the heart: from basic research to clinical evidence","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1055\/s-0032-1301902","article-title":"Predictive factors of left ventricular mass changes after treatment of primary aldosteronism","volume":"44","author":"C Catena","year":"2012","journal-title":"Horm Metab Res"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2165\/11593690-000000000-00000","article-title":"Left heart morphology and function in primary aldosteronism","volume":"19","author":"A Milan","year":"2012","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.108.114140","article-title":"Inappropriate left ventricular mass in patients with primary aldosteronism","volume":"52","author":"M L Muiesan","year":"2008","journal-title":"Hypertension"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1177\/1470320312446240","article-title":"Left ventricle remodeling in men with moderate to severe volume-dependent hypertension","volume":"13","author":"T Indra","year":"2012","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1210\/jc.2011-0354","article-title":"Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study","volume":"96","author":"E Pimenta","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/HJH.0000000000000186","article-title":"KCNJ5 gene somatic mutations affect cardiac remodelling but do not preclude cure of high blood pressure and regression of left ventricular hypertrophy in primary aldosteronism","volume":"32","author":"G P Rossi","year":"2014","journal-title":"J Hypertens"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","article-title":"Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism","volume":"62","author":"G P Rossi","year":"2013","journal-title":"Hypertension"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/HYPERTENSIONAHA.109.141531","article-title":"Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study","volume":"55","author":"K Gaddam","year":"2010","journal-title":"Hypertension"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ajh\/hpu154","article-title":"Adrenalectomy is comparable with medical treatment for reduction of left ventricular mass in primary aldosteronism: meta-analysis of long-term studies","volume":"28","author":"L Marzano","year":"2015","journal-title":"Am J Hypertens"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.surg.2011.02.006","article-title":"Reversal of myocardial fibrosis in patients with unilateral hyperaldosteronism receiving adrenalectomy","volume":"150","author":"Y H Lin","year":"2011","journal-title":"Surgery"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","article-title":"Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism","volume":"30","author":"Y H Lin","year":"2012","journal-title":"J Hypertens"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","article-title":"Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism","volume":"50","author":"C Catena","year":"2007","journal-title":"Hypertension"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000340031","article-title":"Vascular disturbances in primary aldosteronism: clinical evidence","volume":"35","author":"J Widimsky Jr","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/01.HYP.21.6.929","article-title":"Vasodilation to acetylcholine in primary and secondary forms of human hypertension","volume":"21","author":"S Taddei","year":"1993","journal-title":"Hypertension"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/HYPERTENSIONAHA.114.05001","article-title":"Effect of aldosterone-producing adenoma on endothelial function and Rho-associated kinase activity in patients with primary aldosteronism","volume":"65","author":"T Matsumoto","year":"2015","journal-title":"Hypertension"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1210\/jc.2011-1135","article-title":"Endothelial progenitor cells in primary aldosteronism: a biomarker of severity for aldosterone vasculopathy and prognosis","volume":"96","author":"V C Wu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1210\/jc.2006-0101","article-title":"Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism","volume":"91","author":"D Rizzoni","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/00004872-200207000-00032","article-title":"Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension","volume":"20","author":"M L Muiesan","year":"2002","journal-title":"J Hypertens"},{"issue":"S 01","key":"ref49","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1097\/01.hjh.0000467628.01505.f8","article-title":"7d.11: Retinal Arteriolar Structure in Patients with Primary Aldosteronism","volume":"33","author":"M Gosk-Przybylek","year":"2015","journal-title":"J Hypertens"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1097\/HJH.0b013e3281268532","article-title":"Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension","volume":"25","author":"R Holaj","year":"2007","journal-title":"J Hypertens"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/HJH.0000000000000464","article-title":"Long-term effect of specific treatment of primary aldosteronism on carotid intima-media thickness","volume":"33","author":"R Holaj","year":"2015","journal-title":"J Hypertens"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.atherosclerosis.2011.12.003","article-title":"Adrenalectomy improves increased carotid intima-media thickness and arterial stiffness in patients with aldosterone producing adenoma","volume":"221","author":"Y H Lin","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"461","DOI":"10.33549\/physiolres.932344","article-title":"Peripheral arterial stiffness in primary aldosteronism","volume":"61","author":"J Rosa","year":"2012","journal-title":"Physiol Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.amjhyper.2006.02.002","article-title":"Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension","volume":"19","author":"B Strauch","year":"2006","journal-title":"Am J Hypertens"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"C1","DOI":"10.1530\/EJE-12-0899","article-title":"Mineralocorticoid receptor antagonists and renal involvement in primary aldosteronism: opening of a new era","volume":"168","author":"C Catena","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrneph.2012.19","article-title":"Glomerular hyperfiltration: definitions, mechanisms and clinical implications","volume":"8","author":"I Helal","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.0000230444.01215.6a","article-title":"Renal damage in primary aldosteronism: results of the PAPY Study","volume":"48","author":"G P Rossi","year":"2006","journal-title":"Hypertension"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1681\/ASN.2004100878","article-title":"Relative glomerular hyperfiltration in primary aldosteronism","volume":"16","author":"J Ribstein","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1001\/jama.295.22.2638","article-title":"Long-term renal outcomes in patients with primary aldosteronism","volume":"295","author":"L A Sechi","year":"2006","journal-title":"JAMA"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1210\/jc.2008-1851","article-title":"Risk factors associated with a low glomerular filtration rate in primary aldosteronism","volume":"94","author":"M Reincke","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1470320310391331","article-title":"Relative kidney hyperfiltration in primary aldosteronism: a meta-analysis","volume":"12","author":"C C Kuo","year":"2011","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"P Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","article-title":"Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study","volume":"62","author":"S Savard","year":"2013","journal-title":"Hypertension"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"C Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1210\/jc.2013-2805","article-title":"Long-term cardio- and cerebrovascular events in patients with primary aldosteronism","volume":"98","author":"P Mulatero","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.numecd.2013.09.009","article-title":"Primary aldosteronism and essential hypertension: assessment of cardiovascular risk at diagnosis and after treatment","volume":"24","author":"F Turchi","year":"2014","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1210\/jc.2008-2116","article-title":"Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn\u2019s Registry","volume":"94","author":"E Born-Frontsberg","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","article-title":"Observational study mortality in treated primary aldosteronism: the German Conn\u2019s registry","volume":"60","author":"M Reincke","year":"2012","journal-title":"Hypertension"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0035-1565124.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T14:20:31Z","timestamp":1718202031000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0035-1565124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,17]]},"references-count":68,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2015,12,14]]},"published-print":{"date-parts":[[2015,12]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0035-1565124","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,17]]}}}